Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

Inclusion Criteria: * A female subject of childbearing potential who is sexually active using contraception. * Subject is willing to abstain from all sexual contact involving her genitalia for at least 24 hours prior to and 24 hours after study drug administration. * Subject must be neither pregnant nor lactating from Screening throughout the duration of the study. * Subject has 1 of the following: * Menstruating with a stable cycle and has at least 21 non-bleeding days. * Amenorrheic (due to injectable or extended-cycle contraceptives). * Subject is willing to refrain from using vaginal douche products during the treatment period and through the Follow-up Month 4 visit. * Subject has a Pap test interpretation of either low-grade squamous intraepithelial lesions or atypical squamous cells of undetermined significance. * Subject has a uterine cervical sample that is high-risk human papillomavirus positive. Exclusion Criteria: * The Subject has evidence of an uncontrolled, clinically significant medical condition as determined by the investigator. * The Subject has a history of hemorrhagic diatheses or coagulopathy. * The Subject has a history of toxic shock syndrome. * The Subject has received any of the following medications in the timeframes listed below: * 851 (in any form) or an active (non-placebo) human papillomavirus vaccine at any time prior to the screening visit. * In the 4 weeks prior to the screening visit the subject has received: * Interferon th…